The Magazine for Sleep Professionals
Monday, April 20, 2026
Harmony Biosciences Holdings, Inc. has announced an exclusive licensing agreement with Bioprojet to develop, manufacture and commercialize TPM-1116, a highly potent and selective oral orexin-2 receptor (OX2R) agonist that will be evaluated for the treatment of narcolepsy and other sleep/wake disorders. TPM-1116 represents a new chemical series of OX2R agonists […]
A new clinical practice guideline developed by the American Academy of Sleep Medicine provides recommendations for the treatment of central disorders of hypersomnolence. These sleep disorders cause excessive sleepiness despite a sufficient amount of nocturnal sleep. The guideline, available online as an accepted paper in the Journal of Clinical Sleep Medicine, […]
